Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Sure, email away :) I'll copy this here, my ans

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154912
(Total Views: 436)
Posted On: 05/28/2019 7:11:11 AM
Avatar
Posted By: trding
Re: misiu143 #3545
Sure, email away

I'll copy this here, my answer on ihub to "so what?", for completion.

Quote:
At what point are going all in on this stock? Before FDA approval? After first TNBC results? After "funding secured"?



For cancer it is very likely only happen after the first results, though results on the other 8 preclinical studies might help. This issue is only 3%-8% of preclinical studies translate to clinical, so they are getting very little credit

But my points
1) This could be very very big. Much bigger than TNBC. All cancers are in play, with the very high ccr5 expression connected to metastasis for that cancer. That percent could be as low as 20% for a particular cancer type with high ccr5 expression, but 20% of all cancers is a massive number. And if this works, I'd imagine with moderate ccr5 expression is in play.
They choose TNBC because 1) the unmet need making it faster to approval and 2) the high percentage with TNBC that are ccr5 (which I feel is the reason TNBC is so deadly to start with)

2) There are many reasons the preclinical don't translate to clinical. Most are safety issues (which I'm not concerned with), the wrong mice, experiment done incorrectly, wrong dose, etc, etc. With this being shown is almost all common cancers over many different mice models, with many different independent researchers, with many different ccr5 inhibitors, a lot of that risk has been eliminated. RP said the results with leronlimab in the TNBC is amazing, something he has either rarely or never seen in 35 years. So right now I have been not looking at the percentage of success, but the percentage of failure if something has this big of results in this many cancers across this many models. I'm reading to see, I have found a couple links that connects the number of types of preclinical cancer success with drugs that are still in clinical trials (not failed yet). Each cancer type has a correlation, small-lung being the best predictor. But what if it was successful in all preclincial trials? I think our success rate is much higher and has not been factored into the stock price yet.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC...91796a.pdf


(0)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us